Erectile Dysfunction Clinical Trial
— PMD-MSC-ED-01Official title:
Evaluate the Safety and Feasibility of Injecting Placental Matrix-Derived Mesenchymal Stem Cells Into the Penis to Treat the Symptoms of Mild to Moderate Erectile Dysfunction
Verified date | April 2015 |
Source | Z Urology |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
Prospective, open-label, non-randomized, study to be conducted at a single center. Ten subjects will undergo an injection of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs) into the penis for the treatment of mild to moderate erectile dysfunction. Follow up visits will be conducted at 6 weeks, 3 months, 6 months, and 12 months. Subjects will be evaluated for re-injection beginning at 3 months. Eligibility is determined by the clinician based on patient reported treatment satisfaction.
Status | Completed |
Enrollment | 8 |
Est. completion date | March 2015 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 40 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. Men aged 40-70 2. Willing and able to provide written informed consent 3. Chronic, organic erectile dysfunction (ED), duration at least 0.5 years, with baseline International Index of Erectile Function-Erectile Function (IIEF-EF) score greater than or equal to 21 4. Willing to complete questionnaires 5. Involved in a monogamous, heterosexual relationship for at least 3 months with both partners motivated to have or attempt sexual intercourse at least 4 times per month beginning two weeks after study treatment (subject reported) 6. Not interested or able to use oral PDE-5 inhibitor (PDE-5i) drug therapy, and willing to forgo these treatments for the first 6-month period following study treatment (in addition may include a 4-week washout since last PDE-5i use prior to completion of the baseline erectile function assessments and study treatment) 7. Willing to limit alcohol intake and eliminate use of recreational drugs for sexual encounters 8. Willing to undergo an injection 9 Mentally competent and able to understand all study requirements (based on investigator assessment) 10. Willing to be available for all baseline, treatment, and follow up examinations required by protocol 11. Willing to forego participation in any other study throughout the duration of this study Exclusion Criteria: 1. Evidence of prostate cancer which requires additional radiotherapy or other adjuvant therapy 2. Previous pelvic or abdominal radiation therapy 3. Previous, concomitant or scheduled use of anti-androgen therapy 4. Untreated hypogonadism or low serum total testosterone (<200 ng/dL) 5. Clinically evident penile anatomical deformities (e.g., Peyronie's disease) or history of priapism 6. Skin irritation, infection, wound, sore, or disruption in the immediate areas of skin entry for penile injection 7. Use of any non-study treatment for erectile dysfunction within 4 weeks of study treatment and a lack of willingness to continue through 6 months after study treatment 8. Any previous penile implant or penile vascular surgery 9. Current or previous malignancy other than localized prostate cancer 10. Uncontrolled hypertension or hypotension (systolic blood pressure > 170 or <90 mm Hg, and diastolic blood pressure > 100 or < 50 mm Hg) 11. Reported unstable cardiovascular disease (e.g., unstable angina, myocardial infarction within the past 6 months, cardiac failure or life-threatening arrhythmia, congestive heart failure) or symptomatic postural hypotension within 6 months before screening 12. Current urinary tract or bladder infection 13. Drug, alcohol, or substance abuse reported within the last three years (subject reported) Subject's sexual partner < 18 years of age or has any gynecologic problems 14. Major medical conditions, or any other factors that would limit participation in sexual intercourse to less than 4 times per month (subject reported) 15. Weight less than 154lbs/ 70 kg, or BMI greater than or equal to 30 16. Systemic autoimmune disorder 17. Significant active systemic or localized infection 18. Receiving immunosuppressant medications |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Z Urology | Coral Springs | Florida |
Lead Sponsor | Collaborator |
---|---|
Melissa Marchand |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Peak Systolic Velocity with trimix (cm/s) | Baseline | No | |
Other | Peak Systolic Velocity with trimix (cm/s) | 6 weeks | No | |
Other | Peak Systolic Velocity with trimix (cm/s) | 3 months | No | |
Other | Peak Systolic Velocity with trimix (cm/s) | 6 months | No | |
Other | Peak Systolic Velocity with trimix (cm/s) | 12 months | No | |
Other | End Diastolic Velocity with trimix (cm/s) | Baseline | No | |
Other | End Diastolic Velocity with trimix (cm/s) | 6 weeks | No | |
Other | End Diastolic Velocity with trimix (cm/s) | 3 months | No | |
Other | End Diastolic Velocity with trimix (cm/s) | 6 months | No | |
Other | End Diastolic Velocity with trimix (cm/s) | 12 months | No | |
Other | Rigidity test (Pass / Fail) | Baseline | No | |
Other | Rigidity test (Pass / Fail) | 6 weeks | No | |
Other | Rigidity test (Pass / Fail) | 3 months | No | |
Other | Rigidity test (Pass / Fail) | 6 months | No | |
Other | Rigidity test (Pass / Fail) | 12 months | No | |
Other | Stretched Penile Length before trimix (cm/s) | Baseline | No | |
Other | Stretched Penile Length before trimix (cm/s) | 6 weeks | No | |
Other | Stretched Penile Length before trimix (cm/s) | 3 months | No | |
Other | Stretched Penile Length before trimix (cm/s) | 6 months | No | |
Other | Stretched Penile Length before trimix (cm/s) | 12 months | No | |
Other | Post Penile Width with trimix | Baseline | No | |
Other | Post Penile Width with trimix | 6 weeks | No | |
Other | Post Penile Width with trimix | 3 months | No | |
Other | Post Penile Width with trimix | 6 months | No | |
Other | Post Penile Width with trimix | 12 months | No | |
Other | International Index of Erectile Function (IIEF) | Baseline | No | |
Other | International Index of Erectile Function (IIEF) | 6 weeks | No | |
Other | International Index of Erectile Function (IIEF) | 3 months | No | |
Other | International Index of Erectile Function (IIEF) | 6 months | No | |
Other | International Index of Erectile Function (IIEF) | 12 months | No | |
Primary | Peak Systolic Velocity without trimix (cm/s) | Baseline | No | |
Primary | Peak Systolic Velocity without trimix (cm/s) | 6 weeks | No | |
Primary | Peak Systolic Velocity without trimix (cm/s) | 3 months | No | |
Primary | Peak Systolic Velocity without trimix (cm/s) | 6 months | No | |
Primary | Peak Systolic Velocity without trimix (cm/s) | 12 months | No | |
Secondary | End Diastolic Velocity without trimix (cm/s) | Baseline | No | |
Secondary | End Diastolic Velocity without trimix (cm/s) | 6 weeks | No | |
Secondary | End Diastolic Velocity without trimix (cm/s) | 3 months | No | |
Secondary | End Diastolic Velocity without trimix (cm/s) | 6 months | No | |
Secondary | End Diastolic Velocity without trimix (cm/s) | 12 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 | |
Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 |